Contera Pharma announces acquisition by Korean Bukwang Pharmaceutical
JM-010 to enter global development for L-DOPA induced dyskinesia
Contera Pharma was founded by John Bondo Hansen and Mikael Thomsen to focus on the development of new treatments of movement disorders. The lead program JM-010 is in development for treatment of L-DOPA induced dyskinesia (LID). LID is a debilitating condition that affects Parkinson’s disease patients with no approved treatments. JM-010 has shown very promising effects in pre-clinical models of LID. CEO John Bondo Hansen and CSO Mikael Thomsen will continue in their roles at Contera Pharma in Denmark.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.